The CMS approved transitional pass-through payment status and established a new reimbursement code for Dextenza.
The code, C9048, will become effective July 1, according to a press release from Ocular Therapeutix.
The C-code facilitates the reimbursement of Dextenza (dexamethasone ophthalmic insert) until a J-code is approved and becomes effective. Ocular Therapeutix announced earlier this month that the CMS had included Dextenza on its list of products preliminarily recommended for a new dedicated Healthcare Common Procedure Coding System J-code, which would become effective Jan. 1, 2020, if
Uncategorized